AMERITRADE
DATEK
Discover Brokerage
DLJDirect
E-Trade
Schwab




To receive immediate notification of research updates, enter your e-mail address here (ex: name@domain.com):


  CYTR
CYTR is a biotechnology company focused on the development and commercialization of innovative therapeutic products. CYTR's lead product is FLOCOR, which is in pivotal Phase III clinical trials for the treatment of acute sickle cell vaso-occlusive crisis (VOC). CYTR recently announced that its independent Safety and Data Monitoring Board had analyzed data from the first 50 patients of its Phase III trial, and recommended continuation of the trial as planned. We anticipate the trial to be completed by the end of 1999. CYTR is also developing FLOCOR for additional indications, including shock, stroke and acute respiratory disorders. CYTR has a pipeline of technologies in the areas of gene and drug delivery, vaccines and infectious disease. CYTR is trading at a significant discount to biotechnology companies with promising products in Phase III clinical trials, and at roughly the value of cash on hand. We recommend purchase of CYTR for investors tolerant of the risks associated with small-cap equity investments.

SMALLCAPS RESEARCH